Home Who We Are In the News

In the news.

FDA approves Aucatzyl CAR T-cell therapy for acute lymphoblastic leukemia (ALL)

The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat acute lymphoblastic leukemia (ALL).

FDA approves Aucatzyl CAR T-cell therapy for acute lymphoblastic leukemia (ALL)

The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat acute lymphoblastic leukemia (ALL).

FDA approves first engineered T-cell therapy for solid tumor

The FDA approved an engineered T-cell therapy, called a T-cell receptor (TCR) therapy, to treat synovial sarcoma.

FDA approves first engineered T-cell therapy for solid tumor

The FDA approved an engineered T-cell therapy, called a T-cell receptor (TCR) therapy, to treat synovial sarcoma.

Celebrating Laurie Adami’s CAR T-cell anniversary

July 16 has more than one significance for Laurie Adami. It’s the date she met her future husband and the date cancer cell and gene therapy saved her life.

Celebrating Laurie Adami’s CAR T-cell anniversary

July 16 has more than one significance for Laurie Adami. It’s the date she met her future husband and the date cancer cell and gene therapy saved her life.

ACGT awards grant to scientist for remote-controlled CAR T cells

Alliance for Cancer Gene Therapy (ACGT) has awarded a research grant to Crystal Mackall, MD (Stanford University), to develop a sophisticated CAR T-cell therapy that can overcome some of the roadblocks presented by solid tumors.